PDX PHARMACEUTICALS, INC.
Nanoparticle-based immunotherapy co-delivering PLK1 inhibitor, PD-L1 antibody, and CpG oligonucleotide for non-small cell lung cancer
- Sector
- Biotech
- Headquarters
- Portland, OR
- Latest Form D
- $1.6M, Nov 2019
- Total capital
- $11.6M
- Federal grants
- $10.1M
- 15 awards · 2017–2025
- Rank in peer group#50 of 514
- Private capital raised
- $1.6M
- 1 Form D · last Nov 2019
- 83 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 13 pending · first 2022
- Rank in peer group#71 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer$1.3M
- Federal grantHealth and Human S · Phase II · PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer$914K
- Federal grantHealth and Human S · Phase II · Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$933K
- Federal grantHealth and Human S · Phase II · PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer$400K
- Federal grantHealth and Human S · Phase II · Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$933K
- Federal grantHealth and Human S · Phase II · In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response$102K
- Federal grantHealth and Human S · Phase II · Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$378K
- Private capital raisedForm D · SEC · 1st filing$1.6M
Show 8 earlier federal awards
- Federal grantHealth and Human S · Phase II · In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response$2M
- Federal grantHealth and Human S · Phase II · Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$513K
- Federal grantHealth and Human S · Phase II · Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$234K
- Federal grantHealth and Human S · Phase II · Supplement grant for R44CA217534: Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$15K
- Federal grantHealth and Human S · Phase II · Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$1.5M
- Federal grantHealth and Human S · Phase I · Development of topical formulation of siRNA nanoparticle for treating skin diseases$325K
- Federal grantHealth and Human S · Phase I · Development of topical formulation of siRNA-nanoparticle for treating skin diseases$325K
- Federal grantHealth and Human S · Phase II · Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
30months
from PDX PHARMACEUTICALS, INC.’s first federal award to its first private round.
- First federal award · May 2017
- Health and Human S · $225K
- First Form D · Nov 2019
- $1.6M · 1st Form D
- Awards before first raise
- 6 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#50 · top 10%
- Granted patents#71 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Wassana YantaseeResearcherExecutive Officer, DirectorLinked by 5 patents
- Worapol NgamcherdtrakulResearcherExecutive OfficerLinked by $8.8M in grants as PI
- Angela HultDirectorNamed in SEC Form D filings
- Joe GrayDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 18- PendingTherapeutic Constructs For Co-delivery Of Anti-cancer Agent(s) And Immune Checkpoint Inhibitor(s)USPTOApplication 19436736
- GrantedTherapeutic Constructs For Co-delivery Of Anti-cancer Agent(s) And Immune Checkpoint Inhibitor(s)USPTOUS 12,582,658
- PendingImmunotherapeutic Constructs And Methods Of Their UseUSPTOApplication 19047489
Show all 18 patent records
- Therapeutic Constructs For Co-delivery Of Anti-cancer Agent(s) And Immune Checkpoint Inhibitor(s)May 7, 2026 · Application 19436736Pending
- Therapeutic Constructs For Co-delivery Of Anti-cancer Agent(s) And Immune Checkpoint Inhibitor(s)Mar 24, 2026 · US 12,582,658Granted
- Immunotherapeutic Constructs And Methods Of Their UseJun 19, 2025 · Application 19047489Pending
- Therapeutic Constructs For Co-delivery Of Mitotic Kinase Inhibitor And Immune Checkpoint InhibitorAug 13, 2024 · US 12,059,500Granted
- Immunogenic Constructs, Compositions, And Methods For Inducing Immune ResponseMar 7, 2024 · Application 18452418Pending
- Immunogenic Constructs, Compositions, And Methods For Inducing Immune ResponseJul 27, 2023 · Application 18003766Pending
- Therapeutic Constructs For Co-delivery Of Mitotic Kinase Inhibitor And Immune Checkpoint InhibitorJun 20, 2023 · US 11,679,082Granted
- Therapeutic Constructs For Co-delivery Of Mitotic Kinase Inhibitor And Immune Checkpoint InhibitorAug 18, 2022 · Application 17625331Pending
- Immunotherapeutic Constructs And Methods Of Their UseAug 11, 2022 · Application 17625330Pending
- Cross-linked Polymer Modified NanoparticlesJul 7, 2022 · Application 17693262Pending
- Cross-linked Polymer Modified NanoparticlesApr 19, 2022 · US 11,305,024Granted
- Immunogenic Constructs, Compositions, And Methods For Inducing Immune ResponseApr 14, 2022 · Application 17552331Pending
- Immunotherapeutic Constructs And Methods Of Their UseMar 31, 2022 · Application 17549817Pending
- Therapeutic Constructs For Co-delivery Of Mitotic Kinase Inhibitor And Immune Checkpoint InhibitorJan 18, 2022 · US 11,224,573Granted
- Therapeutic Constructs For Co-delivery Of Mitotic Kinase Inhibitor And Immune Checkpoint InhibitorApplication PCTUS2020041852Pending
- Immunogenic Constructs, Compositions, And Methods For Inducing Immune ResponseApplication PCTUS2021041487Pending
- Polymer Modified Nanoparticles For Cytokine DeliveryApplication 63561263Pending
- Immunotherapeutic Constructs And Methods Of Their UseApplication PCTUS2020041844Pending
Related companies, and why
- ELEGEN CORP.Similar federal contract value in Biotech · null in contracts
- GISMO THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- ROCKETML, INC.Similar federal contract value in Biotech · null in contracts
- PHOTOSWITCH BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- AVENZOAR PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- SYNERGYS BIOTHERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .